Profile: Cambrex Corp (CBM.N)

CBM.N on New York Stock Exchange

14.39USD
4:01pm EDT
Price Change (% chg)

$-0.26 (-1.77%)
Prev Close
$14.65
Open
$14.50
Day's High
$14.60
Day's Low
$13.64
Volume
115,057
Avg. Vol
40,074
52-wk High
$15.62
52-wk Low
$8.85

Search Stocks

Cambrex Corporation (Cambrex), incorporated in 1981, is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics. The Company’s business is consisted of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Its products include active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company supplies its products and services globally to generic pharmaceutical companies. The Company’s owns 51% stake in Zenara Pharma (Zenara), which focuses on the formulation of final dosage form products. The Company’s products are sold through a combination of direct sales and independent agents.

Cambrex manufactures over 70 generic APIs, in relatively small quantities for use in niche therapeutics. The Company’s business consists of three manufacturing facilities and one research and development (R&D) center. These facilities manufacture pharmaceutical intermediates, APIs and ingredients derived from organic chemistry. The Company, through IEP GmbH (IEP), designs and licenses biocatalytic enzymes.

Company Address

Cambrex Corp

ONE MEADOWLANDS PLAZA
EAST RUTHERFORD   NJ   7073
P: +1201.8043000
F: +1201.8049852

Search Stocks